BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25140053)

  • 1. The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.
    Kiuchi T; Ortiz-Zapater E; Monypenny J; Matthews DR; Nguyen LK; Barbeau J; Coban O; Lawler K; Burford B; Rolfe DJ; de Rinaldis E; Dafou D; Simpson MA; Woodman N; Pinder S; Gillett CE; Devauges V; Poland SP; Fruhwirth G; Marra P; Boersma YL; Plückthun A; Gullick WJ; Yarden Y; Santis G; Winn M; Kholodenko BN; Martin-Fernandez ML; Parker P; Tutt A; Ameer-Beg SM; Ng T
    Sci Signal; 2014 Aug; 7(339):ra78. PubMed ID: 25140053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.
    Muraoka-Cook RS; Sandahl MA; Strunk KE; Miraglia LC; Husted C; Hunter DM; Elenius K; Chodosh LA; Earp HS
    Mol Cell Biol; 2009 Sep; 29(18):4935-48. PubMed ID: 19596786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling.
    Hartman Z; Zhao H; Agazie YM
    Oncogene; 2013 Aug; 32(35):4169-80. PubMed ID: 23027125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
    Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
    BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Threshold-controlled ubiquitination of the EGFR directs receptor fate.
    Sigismund S; Algisi V; Nappo G; Conte A; Pascolutti R; Cuomo A; Bonaldi T; Argenzio E; Verhoef LG; Maspero E; Bianchi F; Capuani F; Ciliberto A; Polo S; Di Fiore PP
    EMBO J; 2013 Jul; 32(15):2140-57. PubMed ID: 23799367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.
    Haines E; Saucier C; Claing A
    J Biol Chem; 2014 Feb; 289(9):5687-703. PubMed ID: 24407288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
    Haskins JW; Nguyen DX; Stern DF
    Sci Signal; 2014 Dec; 7(355):ra116. PubMed ID: 25492965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cbl and Itch binding sites in ERBB4 CYT-1 and CYT-2 mediate K48- and K63-polyubiquitination, respectively.
    Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
    Cell Signal; 2013 Feb; 25(2):470-8. PubMed ID: 23153581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site.
    Jansen SM; Sleumer LS; Damen E; Meijer IM; van Zoelen EJ; van Leeuwen JE
    Cell Signal; 2009 May; 21(5):810-8. PubMed ID: 19263517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.
    Duan L; Raja SM; Chen G; Virmani S; Williams SH; Clubb RJ; Mukhopadhyay C; Rainey MA; Ying G; Dimri M; Chen J; Reddi AL; Naramura M; Band V; Band H
    J Biol Chem; 2011 Jan; 286(1):620-33. PubMed ID: 20940296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth.
    Wisniewski DJ; Liyasova MS; Korrapati S; Zhang X; Ratnayake S; Chen Q; Gilbert SF; Catalano A; Voeller D; Meerzaman D; Guha U; Porat-Shliom N; Annunziata CM; Lipkowitz S
    J Biol Chem; 2023 Jan; 299(1):102766. PubMed ID: 36470425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer.
    Li Y; Zhou Z; Alimandi M; Chen C
    Oncogene; 2009 Aug; 28(33):2948-58. PubMed ID: 19561640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation.
    Hong SY; Shih YP; Li T; Carraway KL; Lo SH
    Cancer Res; 2013 Aug; 73(16):5266-76. PubMed ID: 23774213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.
    Feng SM; Muraoka-Cook RS; Hunter D; Sandahl MA; Caskey LS; Miyazawa K; Atfi A; Earp HS
    Mol Cell Biol; 2009 Feb; 29(3):892-906. PubMed ID: 19047365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB4 expression in neural progenitor cells (ST14A) is necessary to mediate neuregulin-1beta1-induced migration.
    Gambarotta G; Garzotto D; Destro E; Mautino B; Giampietro C; Cutrupi S; Dati C; Cattaneo E; Fasolo A; Perroteau I
    J Biol Chem; 2004 Nov; 279(47):48808-16. PubMed ID: 15355992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
    Ahmed SF; Buetow L; Gabrielsen M; Lilla S; Sibbet GJ; Sumpton D; Zanivan S; Hedley A; Clark W; Huang DT
    Oncogene; 2021 Mar; 40(12):2149-2164. PubMed ID: 33627783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
    Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
    Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42.
    Hirsch DS; Shen Y; Wu WJ
    Cancer Res; 2006 Apr; 66(7):3523-30. PubMed ID: 16585176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keeping EGFR signaling in check: ubiquitin is the guardian.
    Polo S; Di Fiore PP; Sigismund S
    Cell Cycle; 2014; 13(5):681-2. PubMed ID: 24526125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.